ExodusPoint Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

ExodusPoint Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-59,491	Closed	-$211K	–	1433
2025 Q1	$211K	Sell	59,491 -46,746	-44%	-$166K	﹤0.01%	1288
2024 Q4	$402K	Buy	+106,237	New	+$500K	﹤0.01%	1206
2024 Q1	–	Sell	-72,824	Closed	-$1.07M	–	1461
2023 Q4	$1.07M	Sell	72,824 -501,799	-87%	-$7.69M	0.01%	798
2023 Q3	$10.5M	Buy	574,623 +61,532	+12%	+$1.3M	0.1%	212
2023 Q2	$11.1M	Buy	513,091 +119,187	+30%	+$3.22M	0.09%	228
2023 Q1	$11.6M	Buy	393,904 +189,967	+93%	+$6.6M	0.1%	235
2022 Q4	$7.54M	Buy	203,937 +141,718	+228%	+$5.03M	0.11%	239
2022 Q3	$1.75M	Buy	62,219 +46,206	+289%	+$1.15M	0.02%	856
2022 Q2	$308K	Buy	+16,013	New	+$190K	﹤0.01%	1519

Other funds holding AMLX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ExodusPoint Capital Management's AMLX Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 59,491 shares — an estimated $211K sold.

ExodusPoint Capital Management first reported a position in AMLX in Q2 2022 and held it in 9 quarters. The position peaked at $11.6M in Q1 2023. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

ExodusPoint Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 59,491 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $211K.
ExodusPoint Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 9 quarters.
ExodusPoint Capital Management's Amylyx Pharmaceuticals position peaked at $11.6M in Q1 2023.
131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.